Peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy

Peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy

Peginterferon alfa plus ribavirin is currently the treatment of choice for chronic hepatitis C. Peginterferon alfa-2a (40KD) plus ribavirin has given an overall sustained virological response of 18% in F3/F4 previous nonresponder US patients. We evaluated the effectiveness of peginterferon alfa-2a (...

Full description

Bibliographic Details
Main Authors: E. Parise, H. Cheinquer, D. Crespo, A. Meirelles, A. Martinelli, H. Sette, J. Gallizi, R. Silva, C. Lacet, E. Correa, H. Cotrim, J. Fonseca, R. Paraná, V. Spinelli, W. Amorim, F. Tatsch, M. Pessoa
Format: Article
Language:English
Published: Elsevier
Series:Brazilian Journal of Infectious Diseases
Subjects:
Peginterferon alfa
ribavirin
hepatitis C
safety
efficacy
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702006000100003&lng=en&tlng=en

Internet

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702006000100003&lng=en&tlng=en

Similar Items